Abstract:In systemic AL amyloidosis, the most commonly used frontline therapy over the past decade was bortezomib based. Recently, the combination of daratumumab, alongside bortezomib and dexamethasone (DVD) has been introduced in the UK for second‐line therapy. Our aim was to assess whether a poor response to first‐line therapy can be abrogated by the introduction of daratumumab. In a cohort of 116 patients we demonstrated a high response rate to DVD especially where patients achieved a good response (VGPR/CR) to bortezomib upfront. However, for those with an inadequate response to frontline bortezomib, the impact of DVD was reduced in both the overall response rate and EFS from second‐line therapy, suggesting that daratumumab does not entirely overcome an inadequate frontline response. Summary Bortezomib is regularly used as frontline therapy for systemic AL amyloidosis. We assess the efficacy of second‐line daratumumab‐bortezomib‐dexamethasone (DVD) in AL amyloidosis in bortezomib‐exposed patients. A total of 116 patients treated with second‐line DVD were identified from a prospective observational study of newly diagnosed AL amyloidosis (ALchemy). DVD was initiated in both the relapsed setting or where there was an inadequate response defined as very good partial response (VGPR) or VGPR with organ progression/lack of organ improvement. A complete response (CR)/VGPR to second‐line DVD was achieved in 81 (69.8%) patients. A CR/VGPR was achieved in 67 (79.7%) in those who achieved a VGPR/CR to first line versus 14/32 (43.8%) in those who did not. Where DVD was initiated due to an inadequate response to first line (vs. at relapse), the median event‐free survival (EFS) was 18 vs. 34 months (p = 0.002). If a CR/VGPR was achieved to DVD, the 2‐year EFS was still lower in those with prior inadequate response 54% vs. 66% (p = 0.062). DVD is an efficacious second‐line treatment in systemic AL amyloidosis in a bortezomib‐exposed population. However, the response to DVD is poorer in those with an inadequate response to first‐line bortezomib.

Response rates to second‐line treatment with daratumumab bortezomib dexamethasone (DVD) in relapsed/refractory light chain amyloidosis (AL) after initial Bortezomib‐based regime